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Abstract
Interleukin-6 (IL-6)-mediated activation of signal transducer and activator of transcription 3 
(STAT3) is a mechanism by which chronic inflammation can contribute to cancer and is a 
common oncogenic event. We discovered a pathway the loss of which is associated with persistent 
STAT3 activation in human cancer. We found that the gene encoding the tumor suppressor 
microRNA miR-146b is a direct STAT3 target gene and its expression was increased in normal 
breast epithelial cells but decreased in tumor cells. Methylation of the miR-146b promoter, which 
inhibited STAT3-mediated induction of expression, was increased in primary breast cancers. 
Moreover, we found that miR-146b inhibited nuclear factor κB (NF-κB)-dependent production of 
IL-6, subsequent STAT3 activation, and IL-6/STAT3-driven migration and invasion in breast 
cancer cells, thereby establishing a negative feedback loop. In addition, higher expression of 
miR-146b was positively correlated with patient survival in breast cancer subtypes with increased 
IL6 expression and STAT3 phosphorylation. Our results identify an epigenetic mechanism of 
crosstalk between STAT3 and NF-κB relevant to constitutive STAT3 activation in malignancy 
and the role of inflammation in oncogenesis.
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Introduction
Signal transducers and activators of transcription (STATs) are proteins in a family of 
transcription factors that have key roles in cancer. In particular, the deregulation and 
inappropriate activation of STAT3 plays a central role in cancer pathogenesis (1). In normal 
cells, STAT3 activation is transient and tightly controlled in extent and duration. By 
contrast, in many cancers, STAT3 is constitutively active, leading to continued expression of 
target genes that promote cell proliferation, survival, invasion, and angiogenesis. A major 
driver of STAT3 activation in malignancy is the cytokine interleukin-6 (IL-6) (2), which 
signals through a complex of IL-6 receptor α (IL-6Rα) and gp130 to activate Janus kinases 
(JAKs) and induce tyrosine phosphorylation of STAT3. The importance of IL-6-driven 
STAT3 activation has been demonstrated in multiple tumor types, including breast, lung, 
liver, prostate, pancreatic, colon, head and neck, multiple myeloma, and melanoma (3, 4).
The source of IL-6 can be either paracrine, originating from nearby stromal or inflammatory 
cells, or autocrine, produced by tumor cells (5). Specifically, the transcription factor NF-κB 
regulates the autocrine expression of IL-6 (6) and is a common mediator of cancer 
pathogenesis and development. For example, NF-κB can trigger an epigenetic switch 
leading to neoplastic transformation through induction of IL-6 and STAT3 activation (7, 8). 
Additionally, the signaling cascade of NF-κB, IL-6, and STAT3 promotes proliferation, 
survival, and chemotherapy resistance in breast cancer (9, 10), androgen-independent 
prostate cancer (11, 12), angiosarcoma (13), and colitis-associated cancer (14, 15). 
Therefore, NF-κB-dependent IL-6 production is a driver of STAT3 activation and thus 
STAT3-dependent cellular phenotypes.
Whereas many protein-coding target genes of STAT3 have been characterized, the 
microRNA (miRNA) target genes of STAT3 represent an interesting and relatively 
unexplored field of study. MiRNAs are short, non-coding RNAs that regulate messenger 
RNAs through translational inhibition and transcript degradation (16), and as with STAT3, 
have been found to influence virtually all aspects of tumor biology. The most well-
established STAT3 miRNA target is miR-21, which has myriad oncogenic effects (17). 
IL-6-mediated expression of miR-21 and miR-181b-1 through STAT3 represses the 
translation of transcripts that encode phosphatase and tensin homolog (PTEN) and the 
deubiquitinase cylindromatosis (turban tumor syndrome) (CYLD), respectively, facilitating 
the activation of NF-κB and the maintenance of cellular transformation (8). The miR-17/92 
cluster is also a STAT3 target (18), and STAT3-mediated induction of miR-17 expression in 
particular can confer resistance to MEK inhibitors (19). Lastly, in a model of hepatocellular 
carcinogenesis, STAT3 induces miR-24 and miR-629, which collectively repress hepatocyte 
nuclear factor 4α (HNF4α) and aid in sustaining constitutive IL-6-STAT3 signaling (20).
Given the functional importance of both STAT3 and miRNAs in cancer, the role of STAT3 
as a transcription factor, and the dearth of known STAT3 miRNA targets, we focused on 
elucidating novel STAT3-regulated miRNAs with relevance to cancer. Here, we identified 
miR-146b as a direct STAT3 target gene whose expression is dysregulated in neoplastic 
tissue. Furthermore, we demonstrate the role of miR-146b in a feedback circuit involving 
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STAT3, NF-κB, and IL-6 with relevance to human cancer. Our findings suggest that the 
regulation of miR-146b by STAT3 is a tumor suppressor mechanism whose loss contributes 
to cancer pathogenesis, especially in the context of dual-activation of NF-κB and STAT3, as 
occurs in inflammatory states.
Results
Genome-wide screen for STAT3-regulated miRNAs reveals miR-146b as a STAT target
Our initial goal was to discover STAT3-regulated miRNAs that are key signaling 
modulators. To do so, we generated a cellular system in which STAT3C, a constitutively-
active STAT3 construct (21), is inducibly regulated by doxycycline. Unlike kinase or 
cytokine-based signaling, which may also activate other pathways, this strategy enabled 
specific and focused activation of STAT3. We utilized non-tumorigenic MCF-10A breast 
epithelial cells because, unlike many tumor cell lines, these cells do not exhibit STAT3 
activation at baseline, and they have been used previously to study the biological effects of 
STAT3 (22). Therefore, MCF-10A cells are well-suited for the identification of miRNAs 
dependent upon STAT3 activity. The engineered MCF-10A cells responded robustly to 
doxycycline treatment with induction of STAT3C expression and STAT3 target genes (fig. 
S1, A and B).
An analysis of differentially-expressed miRNAs following STAT3C induction revealed 12 
species with 2-fold or greater change in expression (fig. S1C and table S1). Five of the 12 
passed validation by quantitative real-time polymerase chain reaction (qRT-PCR) (Fig. 1A), 
including miR-21, a known STAT3 target (17). . To distinguish the direct targets of STAT3 
from those regulated indirectly, we analyzed the miRNA primary transcripts for induction 
by IL-6-mediated STAT3 activation while new protein synthesis was blocked (fig. S1D). 
This revealed miR-146b as a direct STAT miRNA target.
STATs directly regulate MiR-146b at its promoter
Induction of STAT3C in MCF-10A cells demonstrates that STAT3 activity alone is 
sufficient to induce miR-146b; a similar result was obtained with an inducible construct of a 
constitutively-active STAT5 (fig. S1, E-F). Furthermore, miR-146b was induced by 
cytokines that activate STAT3 (IL-6) or STAT1 (IFN-γ) (Fig. 1B). Cytokine-stimulated 
induction of miR-146b was abrogated by dominant-negative STAT constructs (Fig. 1C), 
demonstrating that STAT transcriptional activity is necessary in this context. Cytokine-
stimulated activation of STAT5 was not evaluated because MCF-10A cells lack abundance 
of the prolactin receptor (23)(23)((23).
We compared the regulation of miR-146b with that of miR-146a, which shares 91% 
sequence identity, but resides at a distinct genomic locus. MiR-146a is a well-characterized 
NF-κB target (24), but it is not known if NF-κB regulates miR-146b. In MCF-10A cells, 
STAT activation induced the abundance of miR-146b but not miR-146a, whereas NF-κB 
activation induced by TNF-α showed the opposite pattern (Fig. 1D). Moreover, TNF-α 
induced only the abundance of miR-146a and not miR-146b in immortalized mammary 
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epithelial cells (IMECs) (fig. S1G), together suggesting that miR-146b is a target of STAT 
but not NF-κB.
To elucidate how STATs regulate miR-146b at a molecular level, we first analyzed the 3kb 
genomic region upstream of miR-146b. Using 5’ rapid amplification of cDNA ends (RACE), 
the start site for the transcript was mapped to position -741 relative to the primary transcript. 
Two consensus STAT binding motifs were found in islands of high phylogenetic 
conservation located 830 bp and 1700 bp upstream of the primary transcript (Fig. 1E). When 
this 3 kb region was inserted upstream of a luciferase reporter, it conferred responsiveness to 
cytokine treatment and STAT3C (Fig. 1F). Mutagenesis of either STAT site inhibited 
reporter induction, thus establishing both sites as functional. Additionally, electrophoretic 
mobility shift assay (EMSA; Fig. 1G) and ChIP (Fig. 1H) demonstrated direct binding of 
IL-6-activated STAT3 to the distal site. The high GC content around the proximal site 
precluded the ability to quantitate STAT binding by ChIP.
STAT activation induces miR-146b in normal tissue and non-transformed cells, but not in 
tumors or cancer cells
To investigate the regulation of miR-146b in normal physiology, we examined mouse 
mammary epithelium at various developmental stages, because STAT activation is well-
characterized in this context. Prominent induction of miR-146b, but not miR-146a, occurred 
throughout late pregnancy, lactation, and involution (Fig. 2A), paralleling recognized 
patterns of STAT phosphorylation (Fig. 2A) and target gene expression (fig. S2) in the same 
tissue. Thus, miR-146b appears to be a bona fide STAT-regulated gene in vivo. In a wide 
range of cell lines lacking basal STAT activation (fig. S3), the induction of miR-146b 
expression after cytokine treatment was effectively partitioned between a moderate to large 
increased abundance in non-tumorigenic, non-transformed cell lines (derived from 
mammary, pancreatic, and prostate epithelium) and little to no induction in nearly all cancer 
cell lines (Fig. 2B). These data suggest that STAT regulation of miR-146b expression occurs 
under normal physiological conditions, but is lost in malignancy. To examine this further, 
we studied a panel of breast cancer cell lines with constitutively active STAT3. These cells 
did not have increased miR-146b expression relative to that seen in unstimulated, non-
cancerous MCF-10A cells that lack basal STAT3 activation (Fig. 2C). Furthermore, we 
measured the abundance of miR-146b in a cohort of primary invasive breast cancers that had 
activated STAT3 (evident by the tyrosine phosphorylation of nuclear STAT3 detected by 
immunohistochemistry). We found that miR-146b expression did not increase with greater 
STAT3 activation, and in fact decreased (Fig. 2D). This suggests that, in vivo, tumors with 
increased STAT3 activation experience selective pressure to decrease miR-146b expression, 
consistent with a functional role for miR-146b as a tumor suppressor. Together, these 
findings indicate that miR-146b is a STAT-regulated gene under physiological conditions 
but not in cancer cells..
DNA methylation inhibits mir-146b expression in vitro and in vivo
To explain this loss of regulatory capacity on a target gene, we hypothesized that STAT 
regulation of miR-146b was disrupted in malignant cells at the epigenetic level. Given the 
role of DNA methylation in suppressing gene expression in tumor cells, we investigated 
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whether methylation inhibits STAT3 activity at the miR-146b promoter. To address this 
possibility, we first treated the miR-146b luciferase reporter with a CpG methyltransferase 
before transfection into MCF-10A cells. Methylation of this construct (fig. S4A) decreased 
its responsiveness to STAT3C by approximately 70% (Fig. 3A). Next, we examined the 
effect of methylation on endogenous miR-146b expression in multiple breast cancer cell 
lines with constitutive JAK-dependent STAT3 activation (25). Treatment of these cells with 
the demethylating agent 5-azacytidine induced the abundance of both mature miR-146b and 
its primary transcript (Fig. 3B). However, this induction was prevented by co-treatment with 
a JAK inhibitor, demonstrating that both DNA demethylation and STAT3 activity were 
necessary for the induction of miR-146b. Additionally, this induction pattern mirrored that 
of SOCS3 (fig. S4B), which encodes a STAT3-dependent negative regulator and is 
frequently methylated in cancer (1).
To corroborate these findings in primary tumors, we utilized The Cancer Genome Atlas 
(TCGA). This database contains over 500 breast cancer samples with methylation of 
485,000 CpGs measured at single-nucleotide resolution. Methylation at the 6 CpGs closest 
to miR-146b (within 600 bp) was significantly and inversely correlated with expression of 
miR-146b (Fig. 3C and fig. S4C) but not with another STAT3 target miR-21 (fig. S4D). 
Additionally, methylation among the 6 sites was correlated with one another (fig. S4E), 
indicating that they are likely coordinately regulated. To evaluate methylation in this region 
more directly, quantitative methylation-specific PCR (Q-MSP) was performed on genomic 
DNA from non-transformed MCF-10A cells or from three breast cancer cell lines. 
Consistent with the analysis of the TCGA data, no methylation was observed in any of the 
cells in sites between 800 bp and 2 kb upstream of miR-146b. By contrast, analysis of the 
region including CpG sites at −63, −56, and +70 bp showed prominent methylation in all 
three cancer cell lines and none in the MCF-10A (Fig. 3D). Lastly, methylation of the CpG 
island at −56 bp from miR-146b was significantly higher in primary breast tumors compared 
with matched normal breast tissue (Fig. 3E). Thus, numerous lines of evidence show that 
upstream methylation suppresses miR-146b expression, both in cancer cell lines and in 
human tumors, supporting the role of miR-146b as a possible tumor suppressor.
MiR-146b counteracts the NF-κB to IL-6 (NF-κB/IL-6) signaling axis and prevents autocrine 
IL-6-dependent STAT3 activity
Because STAT3-dependent regulation of miR-146b expression was altered between normal 
and tumor cells, we investigated the biological relevance of miR-146b as a STAT3-
responsive gene. MiR-146b targets TRAF6 and IRAK1 mRNA, which encode proteins that 
activate NF-κB (24). Accordingly, transfection of a miR-146b mimic repressed the 
translation of TRAF6 and IRAK1 in multiple breast cancer cell lines (fig. S5A). To 
determine whether induction of endogenous miR-146b could have the same effect, 
MCF-10A cells were treated with IL-6 or IFN-γ; these treatments also decreased the 
abundance of TRAF6 and IRAK1 (Fig. 4A), but this decrease was blunted by a miR-146b 
inhibitor, showing that the effect was dependent on induction of miR-146b. Thus, STAT-
mediated induction of endogenous miR-146b was functionally equivalent to the effects of a 
miR-146b mimic.
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Because IRAK1 and TRAF6 are upstream in the activation of NF-κB, we examined the 
effect of miR-146b on NF-κB activity in cells that have constitutively active NF-κB. 
Introducing a miR-146b mimic into SUM-159 or MDA-MB-468 cells decreased the 
expression of an NF-κB-dependent luciferase reporter gene (Fig. 4B). Similarly, 
introduction of the miR-146b mimic into BT-549, MDA-MB-468, or SUM-159 breast 
cancer cells decreased virtually all NF-κB target genes tested in each of these 3 cell lines 
(Fig. 4C), indicating a substantial suppression of NF-κB activity. Among the genes with 
decreased expression was that which encodes IL-6, which can activate STAT3 in an 
autocrine manner. Therefore, we hypothesized that miR-146b functions in a negative 
feedback loop to counter-regulate NF-κB-dependent IL6 expression and downstream 
activation of STAT3. SiRNAs targeting IL6 or the NF-κB subunit RelA in SUM-159 cells 
reduced the expression of IL6, the tyrosine phosphorylation of STAT3, and the expression of 
STAT3 target genes (Fig. 4D). STAT3 tyrosine phosphorylation was also abolished by 
treatment with a pharmacological inhibitor of JAK or a neutralizing antibody to IL-6 (Fig. 
4E). These results underscore the role of autocrine IL-6 in the activation of STAT3. STAT3 
tyrosine phosphorylation was also inhibited by miR-146b mimic, which additionally 
suppressed autocrine IL-6 secretion into culture medium (Fig. 4, E-F). Furthermore, 
miR-146b-induced inhibition of IL-6-dependent STAT3 activation was accompanied by 
decreased expression of a large panel of STAT3 target genes (Fig. 4G). Alternative 
activation of NF-κB by TNF-α, which occurs independently of TRAF6 and IRAK1, 
reversed all of these effects, increasing the secretion of IL-6 and the expression of NF-κB 
target genes (Fig. 4, E-F, and fig. S5C). These findings establish the role of miR-146b as an 
inhibitor of NF-κB-dependent IL-6 to STAT3 (IL-6/STAT3) signaling.
In MDA-MB-468 and BT-549 cells, the abundance and phosphorylation of STAT3 was 
unaffected by treatment with the IL-6 neutralizing antibody (fig. S5D), and IL6 mRNA was 
substantially lower than that in SUM-159. Correspondingly, the miR-146b mimic did not 
inhibit the phosphorylation of STAT3 (fig. S5A). Thus, the effect of miR-146b on STAT3-
related phenotypes was further characterized in SUM-159 cells.
MiR-146b inhibits IL-6/STAT3-driven migration, invasion, and the mesenchymal transition 
of tumor cells
Given that miR-146b inhibits autocrine IL-6-dependent STAT3 activity, we next examined 
its functional effects in cancer cells. Migration and invasion are promoted by STAT3 (1), so 
we hypothesized that miR-146b inhibits STAT3-dependent cancer cell motility. The 
introduction of miR-146b mimic into SUM-159 cells for 48 hours strongly diminished their 
migration and invasion (Fig. 5, A-D) without affecting cell viability as measured by cellular 
ATP content (fig. S6A). To determine if these effects were specifically to the result of 
inhibition of STAT3, STAT3C was introduced into cells to maintain STAT3 signaling 
independently of autocrine IL-6. STAT3C reversed the miR-146b-induced motility defects 
by roughly 50%, indicating that the phenotype was largely attributable to suppression of 
STAT3.
Cell motility is associated with epithelial-to-mesenchymal transition (EMT), a process also 
promoted by STAT3 (26). Thus, we hypothesized that miR-146b inhibits the mesenchymal 
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phenotype of SUM-159 cells. Indeed, miR-146b caused individual cells to become less 
spindle-shaped and more epithelial in appearance, whereas the overall population appeared 
more clustered, with increased cell-cell contacts (Fig. 5E). In addition, miR-146b caused 
gene expression changes that were consistent with transition to a more epithelial state (Fig. 
5F). STAT3C opposed the morphological effects and some of the gene expression changes 
induced by miR-146b. Overall, our data show that miR-146b inhibits IL-6/STAT3-driven 
migration, invasion, and EMT of cancer cells.
JAK inhibition and miR-146b repletion have a combinatorial effect on tumor viability
JAK inhibitors are under investigation or in clinical use for treating malignancies that have 
constitutively active STAT, including those with IL-6-dependent STAT3 activation (27). 
Treating SUM-159 cells with a pharmacological JAK inhibitor for 96 hours decreased their 
viability (Fig. 5G). However, by shutting off STAT3, JAK inhibition also substantially 
reduced the expression of miR-146b (fig. S6B). Therefore, we hypothesized that JAK 
inhibition and miR-146b repletion together could exert a combinatorial effect on tumor 
viability. Indeed, the combination treatment had a greater effect than either agent alone (Fig. 
5G), perhaps because JAK inhibition by itself decreased STAT3-dependent negative 
feedback regulators, such as miR-146b.
In primary breast cancers, miR-146b expression correlates with patient survival in 
molecular subtypes associated with IL-6-dependent STAT3 activation
Our data suggest that miR-146b centrally mediates a negative feedback circuit connecting 
STAT3 activation to decreased NF-κB activity and IL-6 production, thereby inhibiting 
further STAT3 activity (Fig. 6A). In breast cancer, ER negative tumors (including triple 
negative or basal-like tumors) are most likely to have IL-6/STAT3 signaling (20, 27). 
Consistent with this, SUM-159 cells are triple negative in origin. In the TCGA cohort, ER 
negative and triple negative tumors displayed higher IL6 expression compared with other 
molecular subtypes (Fig. 6B and fig. S7A). Additionally, IL6 expression was strongly 
correlated with the expression of multiple NF-κB target genes (fig. S7B), suggesting that 
IL6 expression in primary tumors is also largely dependent on NF-κB.
To determine the clinical significance of miR-146b, we examined patient survival according 
to miR-146b expression within different molecular subtypes of breast cancer. Higher 
abundance of miR-146b, as assessed by Illumina miRNA-seq, was associated with superior 
overall survival specifically in the subset of patients with ER-negative tumors (Fig. 6C) or 
triple negative tumors (fig. S7C), which are the subtypes most linked to IL-6-dependent 
STAT3 activation. By contrast, there was no significant correlation of miR-146b with 
survival in other breast cancer subtypes, which are less likely to have STAT3 activation. 
This is consistent with our findings in SUM-159 cells, in which the tumor suppressor effects 
of miR-146b were realized largely through suppression of autocrine IL-6 and STAT3 
signaling.
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Discussion
STAT3 induces miR-146b, a negative regulator in cancer
Using an inducible form of constitutively active STAT3, we identified miR-146b as a 
STAT3 target. Although several other miRNA targets of STAT3 have been previously 
reported, miR-21 was the only known target to be identified in our screen. This suggests that 
the target genes of STAT3 are highly context-dependent, varying according to differences in 
epigenetic marks and chromatin structure, expression of transcriptional cofactors, or activity 
of other signaling pathways. We observed this phenomenon for miR-146b as well: Its 
regulation and expression was substantially altered (decreased) in human tumors and cancer 
cell lines compared to non-cancer cells and the normal developing mammary gland (Fig. 2).
In contrast to the pro-oncogenic role of nearly all other known STAT3 target genes, 
published studies have characterized miR-146b as a tumor suppressor. The same is true of 
miR-146a. Although STATs do not regulate miR-146a, it shares overlapping targets with 
miR-146b owing to an identical seed region. Thus, functional effects for miR-146b may be 
inferred from studies of miR-146a. Tumor suppressor activities for both miR-146 isoforms 
have been identified in breast cancer (28, 29), glioblastoma (30, 31), pancreatic cancer (32), 
gastric cancer (33), and androgen-independent prostate cancer (34, 35). These reports have 
identified mRNAs encoding matrix metalloproteinase MMP16, epidermal growth factor 
receptor (EGFR), and Rho-associated, coiled-coil containing protein kinase 1 (ROCK1) as 
targets of miR-146a and miR-146b. Our findings here showed that miR-146b-mediated 
inhibition of STAT3 activity through the NF-κB/IL-6 axis is majorly responsible for the 
tumor suppressor effects of miR-146b in breast cancer.
Despite these functional data, the transcriptional regulation of miR-146b has remained 
poorly understood. Until now, c-fos was the only transcription factor characterized to 
regulate miR-146b at a molecular level (36). That a tumor suppressor like miR-146b is 
regulated by STAT3 may seem surprising because STAT3 is generally regarded as 
mediating oncogenic effects. However, several precedents exist for other STAT3-induced 
negative feedback regulators. A classic example is SOCS3, which inhibits cytokine and 
growth factor signaling, thereby dampening STAT3 activation. Additionally, STAT3 can 
induce miR-125b and the miR-17/92 cluster, which can target STAT3 itself (18, 37, 38).
Intriguingly, the recurring pattern among these factors and miR-146b is inhibition of STAT3 
activity, either directly or indirectly. Thus, STAT3-dependent negative feedback regulators 
may be central to the proper temporal control of STAT3 activity, which in turn is crucial to 
prevent normal STAT3 activation from becoming an oncogenic event. Because the 
dysregulation of negative regulators can shift the net effect of pathway activation toward 
oncogenicity, understanding the negative regulators (such as miR-146b) is crucial to fully 
understanding the role of STAT3 in cancer pathogenesis.
MiR-146b links STAT3 to NF-κB and IL-6 as part of a negative feedback circuit
Our study uncovered a new mechanism of inhibitory crosstalk between STAT3 and NF-κB 
mediated through miR-146b. Based on our model (Fig. 6A), we posit that miR-146b 
normally prevents unchecked STAT3 activation from taking hold in the setting of cell-
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autonomous NF-κB and IL-6 signaling. However, in cancer, this negative feedback 
mechanism is at least partially subverted, permitting the growth and progression of tumors 
dependent on the NF-κB/IL-6/STAT3 pathway. Multiple lines of evidence support this 
model. First, STAT3 and NF-κB are frequently co-activated in tumors (39), and NF-κB-
dependent IL-6 production is a major driver of STAT3 activation in cancer. Second, 
miR-146b was readily inducible in normal mammary physiology and in non-transformed 
cells, but not in human tumors or most cancer cell lines. Third, miR-146b expression was 
suppressed by promoter methylation, which was increased in tumor samples compared to 
normal tissue. Fourth, miR-146b inhibited multiple tumorigenic phenotypes in cancer cells 
that have activation of the NF-κB/IL-6/STAT3 pathway. Fifth, higher miR-146b expression 
was associated with longer patient survival specifically in breast cancer subtypes that exhibit 
increased IL6 expression and STAT3 activation.
Although our work mostly involved models of breast cancer, the high interdependence 
between STAT3 and NF-κB in diverse cancer types suggests a broader role for the STAT3/
miR-146b pathway as a key mechanism of tumor suppression. For example, persistent 
activation of NF-κB, leading to IL-6 production and STAT3 activation, has been reported to 
trigger neoplastic transformation in a number of cell types (7). Thus, STAT3 induction of 
miR-146b may be a general feedback inhibitor of NF-κB-triggered tumorigenesis. In other 
instances, STAT3 activation is the primary event and facilitates oncogenic NF-κB activation 
(40, 41). In this context, concomitant miR-146b induction may ensure NF-κB activity does 
not cross the oncogenic threshold. This network motif, an incoherent feed-forward loop, 
reduces biological noise and is especially suited to the role of miRNAs (42).
Additionally, the NF-κB/IL-6/STAT3 signaling cascade is crucial in multiple tumor types, 
with a prominent example being colitis-associated cancer (CAC) (14, 15). miR-146b shows 
increased abundance in the transition from normal tissue to dysplasia, but decreased 
abundance as dysplasia progresses to CAC (43). This suggests miR-146b is competently 
induced by activated STAT3 in early lesions, but becomes dysregulated during cancer 
progression.
MiR-146b expression displays significance to understanding human cancer
NF-κB, IL-6, and STAT3 are important to breast cancer biology (25, 44); thus, miR-146b 
and the regulatory circuit linking these factors are likely to be important in human cancer. 
First, miR-146b expression decreased with increasing abundance of phosphorylated nuclear 
STAT3 in tumors, indicating it may become subverted in tumors dependent on a high degree 
of activated STAT3. Second, a tumor suppressor role for miR-146b in primary tumors is 
supported by our finding of increased miR-146b promoter methylation in that setting. Third, 
miR-146b expression was positively associated with patient survival in tumors linked to 
IL-6/STAT3 signaling, which agrees with our functional studies in cell lines. Therefore, 
multiple lines of evidence from human tumors indicate that miR-146b functionally interacts 
with STAT3 in a clinically important manner.
Although reliable delivery of miR-146b to tumors is not yet clinically feasible, alternate 
strategies to achieve a similar goal include expression of endogenous miR-146b using 
demethylating agents or developing small molecules to target the key, potentially druggable 
Xiang et al. Page 9
Sci Signal. Author manuscript; available in PMC 2015 January 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
targets of miR-146b, such as IRAK1. Eventually, therapies that inhibit JAK/STAT signaling 
and reconstitute miR-146b activity may be combined to enhance clinical benefit, particularly 
for triple-negative breast cancers, which have relatively poor prognosis and limited 
treatment options.
Although inflammation can promote cancer (45), specific genetic and epigenetic 
perturbations are required for it to switch from being benign to oncogenic. Cancer is still a 
relatively rare outcome of inflammation because of the activity of normal regulatory 
mechanisms. Our study elucidates one such negative feedback circuit involving STAT3, 
miR-146b, NF-κB, and IL-6 with significance to human cancer, thus adding to our 
understanding of how inflammatory networks are regulated in normal and neoplastic tissue.
Materials and Methods
High-throughput microRNA screen
Doxycycline-inducible MCF-10A cells were generated by retroviral transduction with 
pRevTet-On and pRevTRE (Clontech) containing STAT3C-FLAG or STAT5a1*6-FLAG as 
the insert. Cells were untreated or doxycycline-treated (2 μg/ml) in triplicate for 48 hours 
prior to RNA processing using the miRNeasy Mini Kit (Qiagen). The time point was chosen 
due to the kinetics of STAT3C induction, observation of increased miR-21 abundance, and 
previous reports of miRNA maturation requiring 12-24 hours (17). The screen was 
performed at the Molecular Diagnostics Laboratory of Dana-Farber Cancer Institute using a 
TaqMan qRT-PCR-based platform covering approximately 700 miRNAs.
Cell lines and tissue culture
MCF-10A cells were obtained from ATCC and cultured as previously described (46). 
RWPE-1 cells were obtained from ATCC and cultured in Keratinocyte Serum-Free Medium 
(Invitrogen). BT-474 cells were obtained from ATCC and cultured in RPMI-1640 + 10% 
FBS. Immortalized mammary epithelial cells (IMEC; from Myles Brown, DFCI) were 
cultured as previously described (47). Immortalized human pancreatic duct epithelial cells 
(HPDE; from Ming Tsao) were cultured as previously described (48). SUM-159 cells (from 
Kornelia Polyak, DFCI) were grown in a 1:1 mix of DMEM/F12 + 10% FBS and Mammary 
Epithelial Cell Growth Medium (Lonza). T-47D, SKBR3, MCF7, MDA-MB-468, BT-549, 
and RPMI-8226 cells were obtained and cultured as previously reported (49-51). The cell 
lines 8988S (from Ronald De Pinho, MD Anderson Cancer Center), ZR-75 (from Lindsay 
Harris, Yale), A431 (from Martin Hemler, DFCI), and HeLa (from Ronny Drapkin, DFCI) 
were grown in DMEM + 10% FBS. The cell lines MDA-MB-453 (from Lindsay Harris), 
MM.1S (from Kenneth Anderson, DFCI), A375 (from James Mier, Beth Israel-Deaconess 
medical Center, Boston, MA), A549 (from Pasi Janne, DFCI), Kelly (from Rani George, 
DFCI), and ME-180 (from Miriam Barshak) were grown in RPMI-1640 + 10% FBS. HT-29 
cells (from David Pellman, DFCI) were grown in McCoy's 5A + 10% FBS. All cells were 
maintained in a humidified incubator at 37°C with 5% CO2.
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Gene expression analysis
Total RNA, including miRNAs, was harvested using the RNeasy Plus Mini Kit (Qiagen) 
with a modified protocol supplied by the manufacturer (below). For mRNA analysis, RNA 
was reverse transcribed using random hexamers and assayed by qRT-PCR as previously 
described (52). For miRNA analysis, RNA was reverse transcribed with the TaqMan reverse 
transcription kit, followed by qRT-PCR with TaqMan miRNA assays (Life Technologies). 
Primer sequences are given in table S2. Gene expression was analyzed in triplicate as mean 
± SEM, normalized to 18S rRNA or beta actin (mRNA) or U6 snRNA (miRNA) .
Total RNA isolation
Cell pellets were lysed in 270 μl RLT Plus buffer + 1% β-mercaptoethanol and processed by 
QIAshredder and genomic DNA eliminator spin columns. The flow-through was mixed with 
460μl 95% ethanol by pipetting up and down, and then run through an RNeasy spin column. 
The spin column was washed twice with 500 μl RPE buffer (after ethanol addition), spun 
once again to remove residual ethanol, and then eluted with 50 μl RNase-free H2O. All spin 
steps were performed on a benchtop microcentrifuge at room temperature and 14,000 RPM 
for 1 min.
Western blotting and antibodies
Western blotting was performed as previously described (53). Antibodies to phospho-
MAPK (9101), total MAPK (9102), phospho- Tyr705 STAT3 (9131), phospho-Thr308 Akt 
(9275), phospho-Ser473 Akt (9271), total Akt (9272), TRAF6 (4743), and IRAK1 (4504) 
were from Cell Signaling Technology. Phospho-STAT1 (33-3400) antibody was from 
Invitrogen. C-terminal STAT3 antibody (sc-482), N-terminal STAT3 antibody (sc-7179), 
and total STAT1 antibody (sc-346) were from Santa Cruz Biotechnology. Antibody to 
phospho-Ser727 STAT3 was described previously (54). Anti-FLAG (F1804), tubulin 
(T5168), and beta actin antibody (A5316) were from Sigma. All antibodies were used at 
1:10000 dilution for Western blot, except for phospho-Akt antibodies, which were used at 
1:2000. For use in EMSA, 2 μl antibody was pre-incubated with 2 μl nuclear extract on ice 
for 30 min prior to addition of binding buffer and probe. IL-6 neutralizing antibody 
(AB-206-NA) was from R&D Systems and used at 3 μg/ml.
RACE
To determine the transcriptional start site for miR-146b, 5’ - RACE was performed using the 
SMART RACE cDNA amplification kit (CLONTECH) according to the manufacturer's 
instructions.
Luciferase assays
STAT3-responsive m67 and constitutive Renilla luciferase constructs were described 
previously (55). The miR-146b promoter luciferase was created by cloning the 3kb region 
upstream of miR-146b into pGL3 (Promega) using PCR primers: 5’-
ATGTTAACGCGTCAGGCTGGTCTCTTAGGTACTG-3’ and 5’-
TGGCTCCTCGAGCAAAGTTCTTTCAGCCTGGAC-3’. To introduce TT→AA point 
mutations at one or both STAT binding sites, the QuikChange Lightning Site-Directed 
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Mutagenesis Kit (Agilent) was used. Dual-luciferase assays were performed as previously 
described (52) and are analyzed as mean ± SD.
Q-MSP
Genomic DNA (gDNA) was isolated from cultured cell lines using a Blood and Cell Culture 
DNA kit (Qiagen, Inc.) and stored at −20°C before use. 0.5 μg gDNA was used for bisulfite 
treatment with the EZDNA Methylation Kit (Zymo Research) according to the supplier's 
protocol. Methylation of the CpG sites was determined through bisulfite modification of 
gDNA (56) and analyzed by Q-MSP (57). MYOD1 served as internal reference. The primer 
sequences to amplify bisulfite converted CpG sites were designed utilizing MethPrimers 
software (www.ucsf.edu/urogene/methprimer). The miR-146b MSP forward primer was 5’-
TTTATTTATTTTGGGAACGGGAGAC-3’, and the reverse primer was 5’-
GACCTTAACATTAATATTATAACACTACCG-3’. PCR reactions were carried out at 
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. PCR reaction 
was carried out in a 25 μl volume containing 2× SYBR Green PCR master mix (Applied 
Biosystems), 200 nM each primer and 10ng bisulfite-modified genome DNA. Bisulfide-
converted, universally methylated human gDNA (Chemicon) served as a positive control. 
MYOD1 serves as internal reference. Data are mean fold change ± standard deviation of 
three replicates.
Transfection
Plasmid transfection was performed using Fugene HD (Promega). To introduce miRNAs 
(25 nM) or siRNAs (10 nM), cells were reverse-transfected using Lipofectamine 
RNAiMAX (Invitrogen); culture media was changed 24 hours later. Thermo Scientific 
Dharmacon was the source of miR-146b mimic (C-300754-03-0005), control mimic 
(CN-002000-01-05), miR-146b inhibitor (IH-300754-05-0005), and control inhibitor 
(IN-002005-01-05). Control siRNA (D-001210-03) was from Thermo Scientific 
Dharmacon, RelA siRNA (6261) was from Cell Signaling Technology, and IL-6 siRNA 
(sc-39627) was from Santa Cruz Biotechnology.
EMSA
The LightShift EMSA Kit (Pierce) was used according to the manufacturer's protocol. 
STAT binding reactions were performed as previously described (58) using 5’-biotinylated 
25 bp probes. The primer sequences were: wild-type, 5’-
ACCCTCCATTCCCGGAACTTTCAAG-3’, 5’-
CTTGAAAGTTCCGGGAATGGAGGGT-3’; mutant, 5’-
ACCCTCCAAACCCGGAACTTTCAAG-3’, 5’-
CTTGAAAGTTCCGGGTTTGGAGGGT-3’. The Region B probe from the BCL6 gene, 
known to bind STAT3 (53), was used as a control.
Chromatin immunoprecipitation (ChIP)
MCF10A cells were stimulated with 20 ng/ml IL-6 for 15 min. ChIP was performed 
essentially as described (59). Cells were sonicated using a Qsonica sonicator. Lysates were 
immunoprecipitated overnight with a phospho-STAT3 antibody (9131, Cell Signaling 
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Technologies). ChIP product was analyzed for binding to the 1.7 site using the primers 
(AGAGACCAGCCATCCCTTTC and TCAGGGCAGCTCTACTGAGG) by qPCR.
Migration, invasion, and viability assays
For motility assays, 10,000 cells per 24-well were transfected with miRNA or control 
mimic. After 48 hours, cells were detached using trypsin, spun down with trypsin 
neutralizing solution (Lonza), and transferred to the apical chamber in pre-warmed 
DMEM/F12 without additives. Pre-warmed complete SUM-159 media was added to the 
basolateral chamber. Cells were allowed to migrate for 8 hours through polycarbonate 
transwell inserts (Corning) or invade for 24 hours through growth factor-reduced Matrigel-
coated inserts (BD BioCoat). The inserts were then fixed and stained in 0.5% crystal violet + 
6% glutaraldehyde for 30 min, rinsed in ddH2O, and swabbed with pre-wet cotton tips to 
remove cells from the apical surface of the membrane. Migrated or invaded cells were 
counted in triplicate 1 mm2 areas and shown as mean ± SD. Cell Titer Glo (Promega) was 
used to measure cell viability based on cellular ATP concentration.
Enzyme-linked immunosorbent assay (ELISA)
SUM-159 cells were transfected in 6-well plates with control mimic or miR-146b mimic for 
48 hours. Afterward, the media was replaced with 1mL fresh media for 9 hours and 
harvested. Measurement of IL-6 concentration in the conditioned medium was performed 
using the Human IL-6 Quantikine ELISA Kit (R&D) according to the manufacturer's 
instructions.
Drug treatments
5-azacytidine (Sigma) was used at 1 μM for 4 days (SUM-159) or 8 days (MDA-MB-468, 
BT-549). JAK inhibitor 1 (Calbiochem) was used at 1μM, unless indicated otherwise. For 
epigenetic studies, the drugs were refreshed with new media every 2 days. U0126 (10 μM) 
and LY294002 (20 μM) were from Cell Signaling Technology. All drugs were dissolved in 
DMSO; final DMSO volume in cell culture was 0.1-0.2%.
Computational analyses
Level 3 miRNA expression (Illumina miRNA-Seq) and mRNA expression (Agilent 244k 
array), level 2 DNA methylation (Illumina 450k array), and clinical parameters (patient 
survival and ER, PR, HER2 status) were downloaded from The Cancer Genome Atlas 
(TCGA) for the breast cancer data set on September 30, 2012. Pearson correlation, rank-sum 
test, and log-rank test were used for statistical analyses.
Primary breast tumor analysis
Phospho-STAT3 (Tyr705) immunohistochemistry and pathologist scoring of nuclear 
phospho-STAT3 staining in tumor cells were performed as previously described (55). 
Samples underwent miRNA expression profiling using the Nanostring nCounter system, 
followed by log2 transformation and quantile normalization. Statistical analysis was by 
rank-sum test and Pearson correlation.
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Acknowledgments
Funding: This work was supported by a grant from the National Cancer Institute (R01-CA160979), the Brent 
Leahey Fund, and a BCRF-AACR grant for Translational Breast Cancer Research. This work was also supported 
by award Numbers T32GM007753 and F30 CA165740-01 from the National Institute of General Medical Sciences.
References and Notes
1. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. Jun 
28.2007 251:199. [PubMed: 17129668] 
2. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Mar 
20.2012 30:1005. [PubMed: 22355058] 
3. Hedvat M, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in 
solid tumors. Cancer cell. Dec 8.2009 16:487. [PubMed: 19962667] 
4. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J 
Cancer. Nov.2005 41:2502. [PubMed: 16199153] 
5. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer cell. Jan.
2008 13:7. [PubMed: 18167335] 
6. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B 
transcription factor. Molecular and cellular biology. May.1990 10:2327. [PubMed: 2183031] 
7. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 
MicroRNA, and IL6 links inflammation to cell transformation. Cell. Nov 13.2009 139:693. 
[PubMed: 19878981] 
8. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and 
miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. 
Molecular cell. Aug 27.2010 39:493. [PubMed: 20797623] 
9. Ndlovu MN, et al. Hyperactivated NF-(60)B and AP-1 transcription factors promote highly 
accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in 
metastatic breast cancer cells. Molecular and cellular biology. Oct.2009 29:5488. [PubMed: 
19687301] 
10. Matsumoto G, et al. Targeting of nuclear factor kappaB Pathways by 
dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and 
antiangiogenic potential in vivo. Clinical cancer research : an official journal of the American 
Association for Cancer Research. Feb 1.2005 11:1287. [PubMed: 15709200] 
11. Xiao W, et al. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-
binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer 
cells. The Prostate. Dec 1.2004 61:354. [PubMed: 15389813] 
12. Domingo-Domenech J, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to 
docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by 
PS-1145 enhances docetaxel antitumor activity. Clinical cancer research : an official journal of the 
American Association for Cancer Research. Sep 15.2006 12:5578. [PubMed: 17000695] 
13. Yang J, et al. Ikk4a/Arf inactivation with activation of the NF-kappaB/IL-6 pathway is sufficient to 
drive the development and growth of angiosarcoma. Cancer research. Sep 15.2012 72:4682. 
[PubMed: 22836752] 
14. Grivennikov S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and 
development of colitis-associated cancer. Cancer cell. Feb 3.2009 15:103. [PubMed: 19185845] 
15. Liang J, et al. Sphingosine-1-Phosphate Links Persistent STAT3 Activation, Chronic Intestinal 
Inflammation, and Development of Colitis-Associated Cancer. Cancer cell. Dec 22.2012 
Xiang et al. Page 14
Sci Signal. Author manuscript; available in PMC 2015 January 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
16. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. Jan 23.2009 136:215. 
[PubMed: 19167326] 
17. Loffler D, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-
mediated induction of microRNA-21 through a highly conserved enhancer. Blood. Aug 15.2007 
110:1330. [PubMed: 17496199] 
18. Brock M, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor 
type II through a novel STAT3-microRNA cluster 17/92 pathway. Circulation research. May 
22.2009 104:1184. [PubMed: 19390056] 
19. Dai B, et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer 
research. May 15.2011 71:3658. [PubMed: 21444672] 
20. Hatziapostolou M, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates 
hepatocellular oncogenesis. Cell. Dec 9.2011 147:1233. [PubMed: 22153071] 
21. Bromberg JF, et al. Stat3 as an oncogene. Cell. Aug 6.1999 98:295. [PubMed: 10458605] 
22. Dechow TN, et al. Requirement of matrix metalloproteinase-9 for the transformation of human 
mammary epithelial cells by Stat3-C. Proceedings of the National Academy of Sciences of the 
United States of America. Jul 20.2004 101:10602. [PubMed: 15249664] 
23. Neilson LM, et al. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 
signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription 
(Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol. Sep.2007 21:2218. 
[PubMed: 17550976] 
24. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA 
miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of 
the National Academy of Sciences of the United States of America. Aug 15.2006 103:12481. 
[PubMed: 16885212] 
25. Marotta LL, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) 
stem cell-like breast cancer cells in human tumors. The Journal of clinical investigation. Jul.2011 
121:2723. [PubMed: 21633165] 
26. Xiong H, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human 
colorectal cancer epithelial-mesenchymal transition. The Journal of biological chemistry. Feb 
17.2012 287:5819. [PubMed: 22205702] 
27. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase 
inhibitors in cancer and autoimmune disease. Current opinion in pharmacology. Aug.2012 12:464. 
[PubMed: 22819198] 
28. Bhaumik D, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of 
metastatic potential in breast cancer cells. Oncogene. Sep 18.2008 27:5643. [PubMed: 18504431] 
29. Hurst DR, et al. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses 
breast cancer metastasis. Cancer research. Feb 15.2009 69:1279. [PubMed: 19190326] 
30. Katakowski M, et al. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration 
and invasion of glioma. Cancer investigation. Dec.2010 28:1024. [PubMed: 20874002] 
31. Xia H, et al. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. 
Brain research. May 7.2009 1269:158. [PubMed: 19265686] 
32. Li Y, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer research. Feb 15.2010 
70:1486. [PubMed: 20124483] 
33. Hou Z, Xie L, Yu L, Qian X, Liu B. MicroRNA-146a is down-regulated in gastric cancer and 
regulates cell proliferation and apoptosis. Med Oncol. Jun.2012 29:886. [PubMed: 21347720] 
34. Xu B, et al. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and 
in a p-ERK-dependent manner in castration-resistant prostate cancer. The Prostate. Aug 1.2012 
72:1171. [PubMed: 22161865] 
35. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate 
cancer. RNA. Mar.2008 14:417. [PubMed: 18174313] 
36. Shao M, et al. PDGF induced microRNA alterations in cancer cells. Nucleic acids research. May.
2011 39:4035. [PubMed: 21266476] 
Xiang et al. Page 15
Sci Signal. Author manuscript; available in PMC 2015 January 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
37. Liu LH, et al. miR-125b suppresses the proliferation and migration of osteosarcoma cells through 
down-regulation of STAT3. Biochemical and biophysical research communications. Dec 9.2011 
416:31. [PubMed: 22093834] 
38. Zhang M, et al. Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid- derived 
suppressor cells by modulating STAT3 expression. J Immunol. Apr 15.2011 186:4716. [PubMed: 
21383238] 
39. Lee H, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. 
Cancer Cell. Apr 7.2009 15:283. [PubMed: 19345327] 
40. Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation 
of inflammatory signaling circuit driving transformation and tumorigenesis. Molecular cell. Mar 
30.2012 45:777. [PubMed: 22364742] 
41. Tye H, et al. STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent 
of Tumor Inflammation. Cancer cell. Oct 16.2012 22:466. [PubMed: 23079657] 
42. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 
Apr 27.2012 149:515. [PubMed: 22541426] 
43. Kanaan Z, et al. Differential microRNA expression tracks neoplastic progression in inflammatory 
bowel disease-associated colorectal cancer. Human mutation. Mar.2012 33:551. [PubMed: 
22241525] 
44. Liu M, et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic 
mice and tumor stem cell expansion. Cancer research. Dec 15.2010 70:10464. [PubMed: 
21159656] 
45. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. Mar 19.2010 
140:883. [PubMed: 20303878] 
46. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10 A mammary 
epithelial acini grown in three-dimensional basement membrane cultures. Methods. Jul.2003 
30:256. [PubMed: 12798140] 
47. DiRenzo J, et al. Growth factor requirements and basal phenotype of an immortalized mammary 
epithelial cell line. Cancer research. Jan 1.2002 62:89. [PubMed: 11782364] 
48. Ouyang H, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype 
and phenotype. The American journal of pathology. Nov.2000 157:1623. [PubMed: 11073822] 
49. Nelson EA, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting 
STAT3. Blood. Dec 15.2008 112:5095. [PubMed: 18824601] 
50. Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents 
inhibit signal transducer and activator of transcriion 3 (STAT3) signaling. Mol Pharmacol. Nov.
2010 78:903. [PubMed: 20693278] 
51. Walker SR, et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. Jun.
2009 7:966. [PubMed: 19491198] 
52. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory 
region frequently mutated in lymphomas. Oncogene. Jan 11.2007 26:224. [PubMed: 16819511] 
53. Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis 
in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. Jul 15.2005 106:690. [PubMed: 
15802533] 
54. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia 
contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively 
phosphorylated on serine residues. J Clin Invest. Dec 15.1997 100:3140. [PubMed: 9399961] 
55. Alvarez JV, et al. Identification of a genetic signature of activated signal transducer and activator 
of transcription 3 in human tumors. Cancer Res. Jun 15.2005 65:5054. [PubMed: 15958548] 
56. Susan JC, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. 
Nucleic acids research. 1994; 22:2990. [PubMed: 8065911] 
57. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel 
PCR assay for methylation status of CpG islands. Proceedings of the National Academy of 
Sciences. 1996; 93:9821.
58. Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in 
response to Bryostatin 1. Blood. Oct 15.2003 102:3016. [PubMed: 12855573] 
Xiang et al. Page 16
Sci Signal. Author manuscript; available in PMC 2015 January 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
59. Walker SR, et al. STAT5 Outcompetes STAT3 To Regulate the Expression of the Oncogenic 
Transcriptional Modulator BCL6. Molecular and Cellular Biology. Aug 1.2013 33:2879. 2013. 
[PubMed: 23716595] 
60. Akashi H, Han HJ, Iizaka M, Nakamura Y. Growth-suppressive effect of non-steroidal anti-
inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes 
whose expression is influenced by sulindac. Int J Cancer. Dec 15.2000 88:873. [PubMed: 
11093808] 
Xiang et al. Page 17
Sci Signal. Author manuscript; available in PMC 2015 January 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. STAT family members directly regulate miR-146b expression
(A) Genome-wide screen for STAT3-dependent miRNAs. Red and orange: direct and 
indirect STAT targets, respectively; light blue: hits that did not pass validation by qRT-PCR; 
gray: low-confidence targets not evaluated by qRT-PCR due to high screen Ct value (> 30) 
or lack of statistical significance. Data are fold-changes from three biological replicates. (B) 
MiRNA expression in MCF-10A cells treated with IL-6 or IFN-γ (20 ng/ml) relative to 
untreated (untx) cells. (C) MiR-146b expression in cytokine-treated (48 hours) MCF-10A 
cells transfected with empty vector or a dominant-negative STAT construct relative to 
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untreated controls. (D) miRNA expression in cytokine-treated (48 hours) MCF-10A cells 
relative to untreated controls. In (B) to (D), data are representative means ± SE from one of 
2 experiments. (E) Schematic of the miR-146b promoter region (3 kb upstream) with 
consensus STAT binding motifs defined as TTCNNNGAA. TSS, transcription start site. (F) 
Activity of luciferase reporters containing wild-type (WT) or STAT site(s)-mutant (MUT: 
TT→AA) miR-146b promoter in shown in (E) 6 hours after cytokine treatment in wild-type 
MCF-10A (left) or 24 hours after STAT3C transfection in MCF-10A (right). Data are means 
± SD of two independent experiments. (G) EMSA using nuclear extract from IL-6-treated 
(20 ng/ml, 15 min) MCF-10A cells and a probe centered on the 1.7 kb STAT site. Reg B: 
positive control. (H) ChIP for phosphorylated STAT3 bound to the 1.7 kb STAT site in 
unstimulated or IL-6-treated MCF-10A cells. Data are mean ± SD of at least two 
independent experiments.
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Fig. 2. STAT activation mediates miR-146b expression in normal mammary epithelium and non-
transformed cells but not cancer cells
(A) Relative expression of miR-146a and −146b in mouse mammary gland tissue at 
indicated stages (left); immunoblots for activation of STAT1, STAT3, and STAT5 from the 
same samples (right) in two mice. (B) Cytokine induction of miR-146b in cell lines without 
basal STAT activation, measured 48 hours after cytokine treatment. (C) MiR-146b 
expression was measured in 5 breast cancer cell lines with constitutively-active STAT3 or in 
IL-6-stimulated MCF-10A cells, and normalized to U6 snRNA. Data in (B) and (C) are 
representative of two independent experiments (D) Relationship of miR-146b expression 
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and STAT3 phosphorylation in 24 invasive human breast tumor specimens; p=0.003 by 
Pearson correlation.
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Fig. 3. DNA methylation counteracts STAT3 activity at the miR-146b promoter and inhibits 
miR-146b expression in vitro and in vivo
(A) Luciferase activity of the indicated miR-146b reporters, with or without prior treatment 
by SssI methylase, was assessed in MCF-10A cells 24 hours post-transfection with 
STAT3C. Methylation by SssI was confirmed by protection of reporter plasmid from HpaII 
digestion (fig. S4A). (B) Expression of primary and mature miR-146b was assessed in breast 
cancer cells with constitutive STAT3 activation after demethylation by 5-azacytidine alone 
or in combination with JAK inhibitor. (C) Correlation of miR-146b expression (reads per 
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million) and miR-146b promoter CpG methylation in 524 breast cancer samples from 
TCGA. Pearson correlation and the least-squares regression line are shown. (D) Q-MSP 
assessing methylation of CpG sites −63, −56, and +70 bp relative to miR-146b. M control: 
fully methylated sequence. (E) miR-146b promoter methylation assessed in 91 TCGA breast 
cancer samples that have corresponding matched normal tissue (rank-sum test). In (A) and 
(D), data are means ± SD from two biological replicates. In (B), data representative means ± 
SE from one of two independent experiments.
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Fig. 4. miR-146b inhibits NF-κB-dependent IL-6 expression and autocrine IL-6-dependent 
STAT3 activation
(A) Western blot of MCF-10A cells transfected with control or miR-146b inhibitor, then 
treated with IL-6 or IFN-γ (20 ng/ml) for 72 hours to induce miR-146b. Densitometric 
quantitation is shown below. (B) NF-κB-dependent luciferase activity (relative to a Renilla 
luciferase control) in breast cancer cell lines transfected with a miR-146b mimic or control. 
Cells treated with RNAi to the p65 subunit of NF-κB served as a positive control. (C) NF-
κB target gene expression in 3 breast cancer cell lines 72 hours after miR-146b mimic 
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transfection relative to control mimic in each respective cell line. (D) Gene expression and 
STAT3 tyrosine phosphorylation assessed in SUM-159 cells 72 hours after transfection with 
the indicated siRNA pools. (E) Immunoblot of SUM-159 cells treated with JAK inhibitor (2 
hours), IL-6 neutralizing antibody (6 hours), or miR-146b mimic transfection (72 hours). 
Separately (right), cells transfected with miR-146b mimic were also treated with TNF-α (5 
ng/ml). Data are means ± SD from two biological replicates. (F) ELISA measurement of 
IL-6 concentration (mean ± SD) in conditioned medium from SUM-159 cells. (G) 
Expression of STAT3 target genes in SUM-159 cells 72 hours after transfection with 
miR-146b mimic. Data are representative of at least two independent experiments. In (B), 
(C), and (F), qRT-PCR data are representative means ± SE from one of 2 independent 
experiments.
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Fig. 5. MiR-146b inhibits IL-6/STAT3-driven migration, invasion, and mesenchymal phenotype 
of cancer cells
(A-B) Microscopy and quantitation of transwell migration assays of SUM-159 cells, 
transduced with either empty vector or STAT3C, after transfection with control or miR-146b 
mimic. Scale bar, 250μm. (C-D) Experiment performed as in panels A-B but using Matrigel 
invasion assays. (E) Morphological appearance of SUM-159 cells after 72 hours transfection 
with control or miR-146b mimic. Scale bar, 250 μm (upper) and 50 μm (lower). Data and 
images in (A) to (E) are means ± SD from two independent experiments. (F) Presence of 
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epithelial and mesenchymal markers in SUM-159 cells 72 hours after transfection with 
control or miR-146b mimic. Data are representative means ± SE from one of X independent 
experiments. (G) Viability of SUM-159 cells 96 hours after treatment with JAK inhibitor 
(500nM), transfection with miR-146b mimic, or both. Data are means ± SD from three 
biological replicates.
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Fig. 6. Significance of STAT3 regulation of miR-146b in human breast cancers
(A) Schematic representation of the proposed regulatory circuit integrating STAT3, 
miR-146b, NF-κB, and IL-6. (B) IL6 expression in TCGA breast cancer samples according 
to ER status (p = 1.7 × 10−7, rank-sum test). (C) Kaplan-Meier survival curves of upper 
tertile versus bottom tertile of miR-146b expression (read count per sample) in TCGA 
patients with ER-negative breast cancer (log-rank test).
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